Protein Kinase Inhibitors for Targeted Anticancer Therapies, 2nd Edition

Dear Colleagues,

Protein kinase inhibitors are one of the most promising groups of drugs for targeted therapies. According to the latest data, 62 small-molecule protein kinase inhibitors have been approved by the Federal Drug Administration (FDA) (37 in the last 5 years), while at least 150 are currently being investigated in clinical trials. This is primarily due to a better understanding of the complex signaling network formed by kinases and their mutual relationships in signal transduction cascades. Kinase activity controls many of the signaling pathways responsible for major processes associated with cell growth, proliferation, differentiation, and metabolism. However, despite the growing number of inhibitors, many limitations remain in this field. The development of resistance based on intrinsic and extrinsic pathways, genomic alterations of the primary target, and a short response to targeted therapies due to the activation of compensatory signaling pathways are among the main issues.

The aim of this Special Issue is to highlight original research papers and review articles that provide new insights into the discovery of novel protein kinase inhibitors, as well as their application in targeted cancer therapies. Contributions to this Special Issue may focus on exploring new therapeutic targets or identifying novel small molecules, relevant mechanisms, or effective combination therapies.

Dr. Katarzyna Malarz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.